ReVision Implant Secures €4M for Brain Implant Vision Restoration Technology
Summary
ReVision Implant has raised €4 million in an oversubscribed funding round from private investors including existing investors and new European medtech operators. The Belgian neurotechnology company is developing a cortical visual prosthesis that bypasses damaged eyes and optic nerves to transmit visual information directly to the brain's visual cortex. The funding follows FDA Breakthrough Device Designation and will support transition from preclinical development to first-in-human studies scheduled for Q3 2026, including cleanroom infrastructure and team expansion.
Why it matters
This funding addresses one of the most challenging frontiers in neurotechnology: restoring vision in patients for whom no existing therapy works because their retinas and optic nerves are entirely damaged. ReVision's approach of interfacing directly with the visual cortex could open treatment options for millions of blind individuals worldwide. The FDA Breakthrough Device Designation and clear path to first-in-human studies within the year represent meaningful de-risking milestones for this ambitious technology.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial